



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UBROGEPANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
UBROGEPANT	UBRELVY	46273		GPI-10 (6770108000)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient has a trial of or contraindication to ONE triptan (e.g., sumatriptan, rizatriptan)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**

**APPROVAL TEXT:** Renewal requires that the request is for acute treatment of migraines and the patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT]) OR the patient has experienced clinical improvement as defined by ONE of the following: 1) ability to function normally within 2 hours of dose, 2) headache pain disappears within 2 hours of dose, or 3) therapy works consistently in majority of migraine attacks.

If no, do not approve.

**INITIAL DENIAL TEXT:** **\*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **UBROGEPANT (Ubrelvly)** requires the following rule(s) be met for approval:

- A. You are being treated for acute (quick onset) migraine
- B. You are 18 years of age or older
- C. You have previously tried ONE triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

UBROGEPANT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets **ONE** of the following criteria?
  - The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
  - The patient has experienced clinical improvement as defined by **ONE** of the following:
    - Ability to function normally within 2 hours of dose
    - Headache pain disappears within 2 hours of dose
    - Therapy works consistently in majority of migraine attacks

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **UBROGEPANT (Ubrovelvy)** requires the following rule(s) be met for approval:

- A. You are being treated for acute (quick onset) migraine
- B. You meet ONE of the following:
  1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
  2. You have experienced clinical improvement as defined by ONE of the following:
    - a. Ability to function normally within 2 hours of dose
    - b. Headache pain disappears within 2 hours of dose
    - c. Treatment works consistently in majority of migraine attacks

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**UBROGEPANT**

---

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ubrelvy.

**REFERENCES**

- Ubrelvy [Prescribing Information]. Madison, NJ: Allergan; June 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/21

Created: 01/20

Client Approval: 11/20

P&T Approval: 10/19